NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.86
  • Forecasted Upside: 7.03 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$9.21
▲ +0.07 (0.77%)
1 month | 3 months | 12 months
Get New BioCryst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.86
▲ +7.03% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $9.86, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 7.03% upside from the last price of $9.21.
Buy
The current consensus among 10 contributing investment analysts is to buy stock in BioCryst Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2021Royal Bank of CanadaBoost Price TargetSector Perform$7.00 ➝ $9.00High
i
12/7/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
i
11/23/2020Evercore ISIInitiated CoverageOutperform$12.00High
i
10/4/2020Bank of AmericaReiterated RatingBuy$6.00High
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
i
8/28/2020Royal Bank of CanadaReiterated RatingHold$4.50High
i
8/7/2020HC WainwrightReiterated RatingBuy$13.00Low
i
7/6/2020Royal Bank of CanadaReiterated RatingHold$5.00Low
i
6/26/2020JMP SecuritiesBoost Price TargetOutperform$10.00 ➝ $11.00High
i
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
i
6/8/2020Piper SandlerReiterated RatingBuy$10.00Medium
i
Rating by Tyler Van Buren at Piper Sandler
5/7/2020Royal Bank of CanadaReiterated RatingHold$4.00Low
i
5/6/2020Needham & Company LLCReiterated RatingHoldLow
i
5/6/2020Piper SandlerBoost Price Target$8.00 ➝ $10.00Medium
i
5/5/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.00 ➝ $7.00High
i
3/9/2020Needham & Company LLCReiterated RatingHoldHigh
i
11/15/2019Bank of AmericaUpgradeNeutral ➝ Buy$5.00 ➝ $4.00Low
i
11/6/2019Needham & Company LLCReiterated RatingHoldMedium
i
10/31/2019HC WainwrightReiterated RatingBuy$13.00High
i
5/24/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$16.00 ➝ $4.50Low
i
5/23/2019JMP SecuritiesLower Price TargetOutperform$18.00 ➝ $10.00High
i
5/22/2019Jefferies Financial GroupLower Price TargetBuy$13.00 ➝ $8.00High
i
5/22/2019HC WainwrightReiterated RatingBuyMedium
i
4/22/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
4/2/2019JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $18.00High
i
4/2/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $8.00High
i
12/4/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$16.00High
i
11/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
9/5/2018JMP SecuritiesBoost Price TargetOutperform$12.00 ➝ $16.00High
i
8/13/2018HC WainwrightReiterated RatingBuy$13.00Medium
i
Rating by A. Fein at HC Wainwright
8/9/2018Jefferies Financial GroupReiterated RatingBuy$8.50High
i
8/8/2018JPMorgan Chase & Co.Initiated CoverageOverweight$9.00Medium
i
8/7/2018Royal Bank of CanadaReiterated RatingBuy$9.00High
i
7/17/2018Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
i
6/28/2018Seaport Global SecuritiesReiterated RatingNeutralLow
i
Rating by V. Bernardino at Seaport Global Securities
6/22/2018Seaport Global SecuritiesInitiated CoverageNeutralHigh
i
Rating by V. Bernardino at Seaport Global Securities
1/23/2018HC WainwrightReiterated RatingBuy$10.00Medium
i
Rating by A. Fein at HC Wainwright
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$6.00High
i
Rating by Nicholas Keher at Royal Bank of Canada
12/20/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$6.00Medium
i
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/A
i
Rating by A. Fein at HC Wainwright
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$6.00Low
i
9/6/2017HC WainwrightReiterated RatingBuy$10.00High
i
Rating by A. Fein at HC Wainwright
9/6/2017JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Neutral$4.93 ➝ $9.00High
i
9/6/2017Jefferies Financial GroupUpgradeHold ➝ Buy$5.00 ➝ $7.00High
i
9/5/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$6.00 ➝ $9.00High
i
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 ➝ $15.00High
i
8/8/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Kumaraguru Raja at Noble Financial
8/8/2017HC WainwrightReiterated RatingBuyLow
i
Rating by A. Fein at HC Wainwright
5/28/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
5/19/2017Needham & Company LLCReiterated RatingHoldMedium
i
Rating by Serge Belanger at Needham & Company LLC
5/6/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
4/12/2017Needham & Company LLCReiterated RatingHoldLow
i
Rating by Serge Belanger at Needham & Company LLC
3/1/2017HC WainwrightReiterated RatingBuy$10.00N/A
i
2/28/2017Jefferies Financial GroupBoost Price TargetPositive$3.50 ➝ $6.00N/A
i
2/16/2017LADENBURG THALM/SH SHInitiated CoverageBuy$11.00N/A
i
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$8.00N/A
i
1/23/2017(FBRC)Reiterated RatingOutperformN/A
i
Rating by R. Jasuja at (FBRC)
12/16/2016JMP SecuritiesUpgradeMarket Perform ➝ Outperform$10.00N/A
i
11/8/2016HC WainwrightReiterated RatingBuyN/A
i
11/8/2016(FBRC)Reiterated RatingBuy$6.00N/A
i
Rating by christopher james at (FBRC)
9/8/2016(FBRC)Reiterated RatingBuyN/A
i
8/12/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.00 ➝ $8.00N/A
i
8/5/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
8/5/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
8/5/2016Jefferies Financial GroupBoost Price TargetHold$2.00 ➝ $3.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/4/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
7/6/2016(FBRC)Reiterated RatingBuy$6.00N/A
i
6/1/2016Jefferies Financial GroupUpgradeHold ➝ Buy$14.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
5/9/2016HC WainwrightReiterated RatingBuy$10.00N/A
i
Rating by Andrew Fein at HC Wainwright
3/9/2016(FBRC)Reiterated RatingOutperformN/A
i
2/26/2016Noble FinancialReiterated RatingBuy$8.00N/A
i
Rating by Rahul Jasuja at Noble Financial
2/25/2016HC WainwrightReiterated RatingBuy$10.00N/A
i
Rating by Andrew Fein at HC Wainwright
2/11/2016HC WainwrightReiterated RatingBuy$24.00 ➝ $10.00N/A
i
Rating by Andrew Fein at HC Wainwright
2/10/2016Noble FinancialReiterated RatingBuy$21.00 ➝ $8.00N/A
i
Rating by Rahul Jasuja at Noble Financial
2/9/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$14.00 ➝ $2.00N/A
i
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 ➝ $10.00N/A
i
2/9/2016(FBRC)Boost Price TargetOutperform$6.00 ➝ $18.00N/A
i
2/9/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$16.00 ➝ $5.00N/A
i
2/8/2016Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
2/8/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$15.00 ➝ $5.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
(Data available from 1/24/2016 forward)
BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $9.21
$8.87
$9.78

50 Day Range

MA: $7.83
$6.10
$9.24

52 Week Range

Now: $9.21
$1.58
$9.78

Volume

9,074,236 shs

Average Volume

4,909,647 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.03

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCryst Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on BioCryst Pharmaceuticals in the last twelve months: Bank of America Co., Barclays PLC, BTIG Research, Evercore ISI, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, TheStreet, and Zacks Investment Research.

What is the current price target for BioCryst Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for BioCryst Pharmaceuticals in the last year. Their average twelve-month price target is $9.86, suggesting a possible upside of 7.0%. HC Wainwright has the highest price target set, predicting BCRX will reach $14.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for BioCryst Pharmaceuticals in the next year.

What is the current consensus analyst rating for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCRX will outperform the market and that investors should add to their positions of BioCryst Pharmaceuticals.

What other companies compete with BioCryst Pharmaceuticals?

How do I contact BioCryst Pharmaceuticals' investor relations team?

BioCryst Pharmaceuticals' physical mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company's listed phone number is 919-859-1302 and its investor relations email address is [email protected] The official website for BioCryst Pharmaceuticals is www.biocryst.com.